Estudo de pembrolizumabe mais quimioterapia versus placebo mais quimioterapia para câncer de mama metastático ou inoperável HR+/HER2- localmente recidivante
The safety and efficacy of pembrolizumab plus the investigator’s choice of chemotherapy will be assessed compared to placebo plus the investigator’s choice of chemotherapy in the treatment of chemotherapy-candidate hormone receptor-positive,